Skip to main content

Table 1 Patient and transplant characteristics

From: Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study

  7.5 mg group (N = 203) 10.0 mg group (N = 205) P
Patient age, median (range), years 28 (14–59) 26 (14–57) 0.324
Gender, male/female, n (%) 139 (68.5)/64 (31.5) 139 (67.5)/66 (32.2) 0.885
Primary diseases, n (%)    0.483
 AML (cytogenetics) 99 (48.8) 95 (46.3)  
  Better risk 8 (8.1) 7 (7.4)  
  Intermediate risk 41 (41.4) 41 (43.1)  
  Poor risk 36 (36.4) 32 (33.7)  
  Unknown 14 (14.1) 15 (15.8)  
 ALL 94 (46.3) 94 (45.6)  
  Ph positive 29 (30.9) 31 (33.0)  
  Ph negative 65 (69.1) 63 (67.0)  
 ABL/ALAL 10 (4.9) 16 (7.8)  
Number of courses of chemotherapy before transplantation, median (range) 3 (3–9) 3 (3–7) 0.875
Status of primary disease, n (%)    0.318
 CR1 155 (76.4) 143 (69.7)  
 ≥ CR2 10 (4.9) 12 (5.9)  
 Non-CR 38 (18.7) 50 (24.4)  
Conditioning, n (%)    0.164
 Standard myeloablative regimen 165 (81.3) 155 (75.6)  
 Intensified conditioning 38 (18.7) 50 (24.3)  
No. of HLA mismatched, n (%)    0.479
 1 14 (6.9) 15 (7.3)  
 2–3 51 (25.1) 62 (30.2)  
 4–5 138 (68.0) 128 (62.1)  
Donor age, median (range), years 38 (10–59) 40 (15–59) 0.326
Donor–recipient sex match, n (%)    0.850
 Male–male 90 (44.3) 92 (44.9)  
 Male–female 41 (20.2) 47 (22.9)  
 Female–male 55 (27.1) 52 (25.4)  
 Female–female 17 (8.4) 14 (6.8)  
CMV serostatus, n (%)    0.906
 D−/R− 8 (3.9) 10 (4.9)  
 D+/R− 7 (3.4) 7 (3.4)  
 D−/R+ 5 (2.5) 7 (3.4)  
 D+/R+ 183 (90.1) 181 (88.3)  
EBV serostatus, n (%)    0.940
 D−/R− 9 (4.4) 10 (4.9)  
 D+/R− 47 (23.2) 50 (24.3)  
 D−/R+ 34 (16.7) 30 (14.6)  
 D+/R+ 113 (55.7) 115 (56.1)  
Median CD34+ cells per graft, × 106/kg (range) 2.26 (0.32–7.37) 2.58 (0.71–7.39) 0.205
  1. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, ABL acute biphenotypic leukemia, ALAL acute leukemia of ambiguous lineage, CR complete remission